BRPI0820832A2 - Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica. - Google Patents

Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.

Info

Publication number
BRPI0820832A2
BRPI0820832A2 BRPI0820832-8A BRPI0820832A BRPI0820832A2 BR PI0820832 A2 BRPI0820832 A2 BR PI0820832A2 BR PI0820832 A BRPI0820832 A BR PI0820832A BR PI0820832 A2 BRPI0820832 A2 BR PI0820832A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
kit
treatment method
cancer treatment
Prior art date
Application number
BRPI0820832-8A
Other languages
English (en)
Inventor
Jan Olof G Karlsson
Tino Kurz
Rolf Andersson
Original Assignee
Pledpharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pledpharma Ab filed Critical Pledpharma Ab
Publication of BRPI0820832A2 publication Critical patent/BRPI0820832A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0820832-8A 2007-12-14 2008-12-12 Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica. BRPI0820832A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US601007P 2007-12-14 2007-12-14
PCT/SE2008/051450 WO2009078794A1 (en) 2007-12-14 2008-12-12 Compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0820832A2 true BRPI0820832A2 (pt) 2015-06-16

Family

ID=40795764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820832-8A BRPI0820832A2 (pt) 2007-12-14 2008-12-12 Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.

Country Status (12)

Country Link
US (2) US8377969B2 (pt)
EP (1) EP2224925B1 (pt)
JP (1) JP5484352B2 (pt)
KR (2) KR101678866B1 (pt)
CN (1) CN101917993B (pt)
AU (1) AU2008339091B2 (pt)
BR (1) BRPI0820832A2 (pt)
CA (1) CA2708113C (pt)
ES (1) ES2552734T3 (pt)
IL (1) IL206189A (pt)
RU (1) RU2491282C2 (pt)
WO (1) WO2009078794A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820832A2 (pt) 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
KR20150080616A (ko) * 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
CN110139673B (zh) * 2016-11-14 2022-03-22 卡尔森图纳投资公司 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
AU1770299A (en) * 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
BRPI0820832A2 (pt) 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.

Also Published As

Publication number Publication date
JP5484352B2 (ja) 2014-05-07
EP2224925A4 (en) 2011-01-12
JP2011506434A (ja) 2011-03-03
WO2009078794A1 (en) 2009-06-25
EP2224925A1 (en) 2010-09-08
HK1151971A1 (en) 2012-02-17
CA2708113A1 (en) 2009-06-25
ES2552734T3 (es) 2015-12-01
AU2008339091B2 (en) 2014-08-07
US20100298271A1 (en) 2010-11-25
KR101678865B1 (ko) 2016-11-23
US8633174B2 (en) 2014-01-21
IL206189A0 (en) 2010-12-30
US20130157983A1 (en) 2013-06-20
RU2491282C2 (ru) 2013-08-27
KR20160036107A (ko) 2016-04-01
CN101917993A (zh) 2010-12-15
AU2008339091A1 (en) 2009-06-25
US8377969B2 (en) 2013-02-19
CN101917993B (zh) 2013-08-21
CA2708113C (en) 2017-08-22
RU2010129038A (ru) 2012-01-20
EP2224925B1 (en) 2015-09-09
IL206189A (en) 2016-06-30
KR101678866B1 (ko) 2016-11-23
KR20100103510A (ko) 2010-09-27

Similar Documents

Publication Publication Date Title
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: EGETIS THERAPEUTICS AB (SE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.